Skip to main content
Full access
Editorials
Published Online: 1 February 2025

Varenicline as a First-Line Treatment for Individuals With Current Major Depressive Disorder Who Smoke Cigarettes

Publication: American Journal of Psychiatry
In this issue, Kypriotakis and colleagues (1) present novel data from the EAGLES trial (Evaluating Adverse Events in a Global Smoking Cessation Study) demonstrating the safety of varenicline, bupropion, and nicotine replacement therapy (NRT) for cessation of cigarette smoking for people with a current or past diagnosis of major depressive disorder (MDD). Because the authors examined current and past MDD separately, they were able to demonstrate that all three pharmacological treatments improved cessation outcomes compared to placebo for people with past MDD. Only varenicline, however, demonstrated improved cessation outcomes compared to placebo for people with current MDD. Similarly, in Cinciripini and colleagues’ (2) analysis of the EAGLES data, 31.2% of people with depression (a combined group with past and/or current MDD) reported continuous abstinence using varenicline, representing the best outcome of the four conditions (compared with 23.0% receiving bupropion, 22.6% receiving NRT, and 13.4% receiving a placebo). These findings have important clinical implications for determining first-line tobacco treatments for people with current MDD.
These data add to the evidence that pharmacological treatments for tobacco cessation are safe for people with depression and that mental health symptoms not only do not worsen but improve with tobacco cessation (35). We are unaware of any pharmacological properties of varenicline that would suggest that it has a direct effect on depressive symptoms. It is reasonable to assume that varenicline’s superior effect on quitting is associated with decreased depressive symptoms. One study, however, found that depressive symptoms decreased for participants with schizophrenia spectrum disorders who received varenicline treatment and behavioral interventions for cigarette smoking cessation regardless of their cessation status (i.e., quit smoking vs. continued smoking) (6), thus indicating that it is not simply quitting cigarette smoking that accounts for the decreased depression. It remains possible, however, that the behavioral intervention, rather than the varenicline itself, contributed to the effect on depression.
The Kypriotakis et al. study and other EAGLES trial data (7) demonstrate the safety of varenicline for individuals with psychiatric comorbidity, and the U.S. Food and Drug Administration removed the black box warning for varenicline related to suicidal thoughts and behaviors in 2015 (8); however, many prescribers remain hesitant to prescribe varenicline to individuals with psychiatric comorbidity (9). This hesitation is not limited to varenicline, as few prescribers provide general tobacco treatment for their patients. Indeed, a survey of U.S. psychiatrists found that only a minority reported that they assist with a quit plan (15.9%), with time constraints and competing factors commonly named as barriers to discussing tobacco use cessation (10). It will be critical to find ways that allow psychiatrists to integrate tobacco treatment into their settings while minimizing barriers to providing this type of care. It may be useful for psychiatrists to develop partnerships that allow them to work collaboratively with other mental health professionals, especially those who may provide counseling, to aid the integration of tobacco treatment into their patients’ care.
As seen in Cinciripini and colleagues’ results (2), summarized above, even with the best outcomes from pharmacological treatment, the majority of people with depression do not achieve abstinence from tobacco, meaning that we need to continue to work to develop treatment plans that improve outcomes. Consistent with most cigarette smoking treatment trials, participants in the EAGLES trial received only 10 minutes of counseling at each of the 12 study visits. Although the 2008 Public Health Service guideline (11) reports that up to 10 minutes of counseling per session is associated with 1.6 times the chances and more than 10 minutes of counseling with 2.3 times the chances of cigarette abstinence as compared to no contact, 10 minutes of counseling per session is a much smaller dose of counseling compared to what would be expected for other substance use disorders, especially when comorbid depression is present. There are multiple types of counseling that have demonstrated efficacy for both depression and tobacco use disorder independently (e.g., acceptance and commitment therapy, cognitive-behavioral therapy, behavioral activation). In research examining whether integrating depression-focused treatment with tobacco cessation–focused treatment yields improved abstinence outcomes for people with depression compared to tobacco cessation–focused treatment alone, there has been only mixed support (1214); however, given the support for varenicline and depression, it makes sense to examine the pairing of varenicline with more intensive doses of these counseling approaches as compared to a brief, 10-minute dose of cessation counseling for individuals with depression. One study examining varenicline and intensive counseling (eight 45-minute sessions) for individuals with depression who smoked cigarettes found that quit rates were 32.3% among those who attended at least 75% of their counseling sessions and only 2.7% for those who attended fewer sessions (15). While directionality cannot be inferred from these data, this finding suggests the need for further research on varenicline paired with intensive psychosocial interventions that are relevant to both depression and tobacco use.
While people with depression are a key priority group related to tobacco disparities (e.g., greater prevalence of and/or consequences from tobacco use, greater difficulty in quitting tobacco use), it is also important to remember that there are individuals with depression who belong to additional tobacco-related disparity groups, such as women, individuals of sexual and gender minoritized status, individuals of racial and ethnic minoritized status, and individuals with lower socioeconomic status (16, 17). In fact, the prevalence of tobacco use among people with depression varies by these factors (e.g., 1820). For example, 2014 data from a national sample of individuals in the United States showed that, beyond a higher prevalence of cigarette smoking for people with depression (34.0%) compared to people without depression (19.9%), larger disparities were found when taking socioeconomic status into account (20). Among individuals with depression, the prevalence of cigarette smoking was nearly two times higher for those with lower incomes (46.3%) compared to those with higher incomes (24.4%).
It is important to consider potential differences in treatment outcomes by sociodemographic subgroups to ensure that all individuals with depression benefit from the most efficacious and effective treatments for tobacco cessation. In the Kypriotakis et al. study, the majority of people with current and past MDD were women (65.9%–66.7%), and the majority of people in the full sample identified as White race (78.9%–83.9%). There are subgroup differences in cigarette smoking cessation by gender and race, with evidence that women and individuals identifying as Black race have more difficulty with cigarette smoking cessation (e.g., 21, 22). With regard to pharmacological treatment efficacy by gender, data pooled from 32 clinical trials showed that the efficacy of varenicline, bupropion, and NRT was similar for men, while varenicline had better outcomes than bupropion and NRT for women (23), with similar results found in a study of real-world effectiveness of pharmacological tobacco treatments (24). With regard to race, a separate analysis of EAGLES data demonstrated that while varenicline, bupropion, and NRT had better efficacy than placebo for White individuals, only varenicline had better efficacy than placebo for Black individuals (25). While these findings suggest the benefits of selecting varenicline as a first-line tobacco treatment across gender and racial groups, it is important to note that there is less evidence for how varenicline, bupropion, and NRT differ in efficacy or effectiveness for other priority tobacco-related disparity groups, such as those from lower socioeconomic status or those with sexual and gender minoritized identities.
Together, the existing data suggest that varenicline should be considered a first-line treatment for individuals with current MDD who smoke cigarettes. Varenicline not only appears to be efficacious for this population but also, importantly, is safe. Prescribers who experience barriers to providing tobacco cessation treatment can collaborate with mental health providers who may provide intensive counseling. Prescribers can also recognize the intersectional identities of their patients and the impact of these identities on tobacco use and tobacco-related disparities (17), as well as the potentially important information provided by secondary analysis of clinical trials and treatment studies that focus on individuals from priority tobacco-related disparity groups. As alluded to above, counseling interventions that are appropriate for both tobacco cessation and the alleviation of depression may be reasonable targets for future research to further enhance treatment outcomes. In addition, the effects of varenicline on depressive symptoms in those who do and who do not quit smoking while using varenicline would be another area for further study. Such studies should control for the behavioral interventions provided and should also be conducted in individuals who are not trying to quit smoking cigarettes, in order to control for mood effects associated with successful quitting. Ultimately, these ongoing clinical and research efforts can help ensure that people with depression, a critical tobacco-related disparity group, receive the most efficacious and effective treatments to help them achieve long-term abstinence from tobacco and reduce tobacco-related consequences.

References

1.
Kypriotakis G, Cinciripini PM, Green CE, et al: Effects of varenicline, bupropion, nicotine patch, and placebo on treating smoking among persons with current or past major depressive disorder: secondary analysis of a double-blind, randomized, placebo-controlled trial. Am J Psychiatry 2025; 182:174–186
2.
Cinciripini PM, Kypriotakis G, Green C, et al: The effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among smokers with major depression: a randomized clinical trial. Depress Anxiety 2022; 39:429–440
3.
Taylor GM, Lindson N, Farley A, et al: Smoking cessation for improving mental health. Cochrane Database Syst Rev 2021; 3:CD013522
4.
Liu NH, Wu C, Pérez-Stable EJ, et al: Longitudinal association between smoking abstinence and depression severity in those with baseline current, past, and no history of major depressive episode in an international online tobacco cessation study. Nicotine Tob Res 2021; 23:267–275
5.
Wu AD, Gao M, Aveyard P, et al: Smoking cessation and changes in anxiety and depression in adults with and without psychiatric disorders. JAMA Netw Open 2023; 6:e2316111
6.
Cather C, Hoeppner S, Pachas G, et al: Improved depressive symptoms in adults with schizophrenia during a smoking cessation attempt with varenicline and behavioral therapy. J Dual Diagn 2017; 13:168–178
7.
Anthenelli RM, Benowitz NL, West R, et al: Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016; 387:2507–2520
8.
FDA Drug Safety Communication: FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings. Silver Spring, MD, US Food and Drug Administration, 2016. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-description-mental-health-side-effects-stop-smoking
9.
Skoloda D, Dowd-Green C, Burdalski C, et al: A pragmatic review of varenicline prescribing practices. J Am Pharm Assoc (2003) 2023; 63:832–837.e1
10.
Young WJ, Delnevo CD, Singh B, et al: Tobacco treatment knowledge and practices among US psychiatrists. Community Ment Health J 2023; 59:185–191
11.
Fiore MC, Jaén CR, Baker TB, et al: Treating Tobacco Use and Dependence: 2008 Update (Clinical Practice Guideline). Rockville, MD, US Department of Health and Human Services, Public Health Service, May 2008
12.
Hall SM, Tsoh JY, Prochaska JJ, et al: Treatment for cigarette smoking among depressed mental health outpatients: a randomized clinical trial. Am J Public Health 2006; 96:1808–1814
13.
Brown RA, Kahler CW, Niaura R, et al: Cognitive-behavioral treatment for depression in smoking cessation. J Consult Clin Psychol 2001; 69:471–480
14.
van der Meer RM, Willemsen MC, Smit F, et al: Effectiveness of a mood management component as an adjunct to a telephone counselling smoking cessation intervention for smokers with a past major depression: a pragmatic randomized controlled trial. Addiction 2010; 105:1991–1999
15.
Schnoll R, Barrila GM, Dalsimer S, et al: Treatment adherence in a smoking cessation clinical trial for individuals with current or past major depressive disorder: predictors and association with cessation. Addict Behav 2023; 143:107686
16.
Weinberger AH, Steinberg ML, Mills SD, et al: Assessing sex, gender identity, sexual orientation, race, ethnicity, socioeconomic status, and mental health concerns in tobacco use disorder treatment research: measurement challenges and recommendations from a Society for Research on Nicotine and Tobacco pre-conference workshop. Nicotine Tob Res 2022; 24:643–653
17.
Sheffer CE, Williams JM, Erwin DO, et al: Tobacco-related disparities viewed through the lens of intersectionality. Nicotine Tob Res 2022; 24:285–288
18.
Loretan CG, Wang TW, Watson CV, et al: Disparities in current cigarette smoking among US adults with mental health conditions. Prev Chronic Dis 2022; 19:E87
19.
Lin SC, Gathua N, Thompson C, et al: Disparities in smoking prevalence and associations with mental health and substance use disorders in underserved communities across the United States. Cancer 2022; 128:1826–1831
20.
Weinberger AH, Bandiera FC, Leventhal AM, et al: Socioeconomic disparities in smoking among US adults with depression, 2005–2014. Am J Prev Med 2018; 54:765–775
21.
Smith PH, Bessette AJ, Weinberger AH, et al: Sex/gender differences in smoking cessation: a review. Prev Med 2016; 92:135–140
22.
Kulak JA, Cornelius ME, Fong GT, et al: Differences in quit attempts and cigarette smoking abstinence between Whites and African Americans in the United States: literature review and results from the International Tobacco Control US Survey. Nicotine Tob Res 2016; 18:S79–S87
23.
Smith PH, Weinberger AH, Zhang J, et al: Sex differences in smoking cessation pharmacotherapy comparative efficacy: a network meta-analysis. Nicotine Tob Res 2017; 19:273–281
24.
Smith PH, Zhang J, Weinberger AH, et al: Gender differences in the real-world effectiveness of smoking cessation medications: findings from the 2010–2011 Tobacco Use Supplement to the Current Population Survey. Drug Alcohol Depend 2017; 178:485–491
25.
Nollen NL, Ahluwalia JS, Sanderson Cox L, et al: Assessment of racial differences in pharmacotherapy efficacy for smoking cessation: secondary analysis of the EAGLES randomized clinical trial. JAMA Netw Open 2021; 4:e2032053

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 139 - 141

History

Accepted: 15 November 2024
Published online: 1 February 2025
Published in print: February 01, 2025

Keywords

  1. Smoking
  2. Major Depressive Disorder
  3. Substance-Related and Addictive Disorders
  4. Nicotine

Authors

Details

Andrea H. Weinberger, Ph.D. [email protected]
Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY (Weinberger); Department of Epidemiology and Population Health and Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, NY (Weinberger); Department of Psychiatry, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ (Steinberg).
Marc L. Steinberg, Ph.D.
Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY (Weinberger); Department of Epidemiology and Population Health and Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, NY (Weinberger); Department of Psychiatry, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ (Steinberg).

Notes

Send correspondence to Dr. Weinberger ([email protected]).

Competing Interests

The authors report no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Figures

Tables

Media

Share

Share

Share article link

Share